Efficacy and toxicity of 8 day methotrexate/folinic acid regimen in the management of low risk gestational trophoblastic neoplasia: a prospective observational study
Keywords:Gestational trophoblastic neoplasia, Methotrexate, Toxicity
Background: Gestational trophoblastic neoplasia (GTN) is a rare malignancy that arises from abnormal proliferation of trophoblastic cells. Low risk GTN responds well to single agent chemotherapy with good survival rate. Objective of the study was to assess the efficacy and toxicity of methotrexate chemotherapy in low risk GTN patients receiving 8-day methotrexate (MTX)/folinic acid (FA) regimen. A prospective observational study done in a tertiary care hospital in South India.
Methods: This prospective observational study was conducted at a tertiary care hospital in south India between July 2015 and July 2018 and included 56 patients with low risk GTN treated with 8-day MTX/FA regimen.
Results: Among the 56 patients treated, complete remission was achieved in 50 (89.3%). Molar pregnancy was the most common preceding pregnancy event (96.7%) and 63.3% of them developed GTN within 4 months of evacuation. Six non responders were treated with EMACO regimen and achieved complete remission. The most common toxicities were mucositis (46.4%) and neutropenia (17.8%). Overall survival of low risk GTN was 100% at the end of median follow up period of 14.4 months.
Conclusions: For patients with low risk GTN, 8-day MTX/FA regimen is associated with a high rate of remission and low toxicity.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717-29.
Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2018;143(2):79-85.
Al-Husaini H, Soudy H, Darwish A, Ahmed M, Eltigani A, Edesa W, et al. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience. Clin Transl Oncol. 2015;17:409-15.
McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 2002;20:1838-44.
Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997;15:2636-43.
Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;2016(6):CD007102.
Goldstein DP, Berkowitz RS, Horowitz NS. Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015;15:1293-304.
Maestá I, Nitecki R, Horowitz NS, Goldstein DP, Moreira FSM, Elias KM, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018;148:161-7.
Apia GS, Gupta JS, Maheshwari A, Deodhar K, Kerkar RA, et al. Outcome of gestational trophoblastic neoplasia: Experience from a tertiary cancer centre in India. Clin Oncol. 2014;26:39-44.
Anfinan N, Sait K, Sait H. Gestational trophoblastic disease in the western region of Saudi Arabia (single-institute experience). Eur J Obstet Gynecol Reprod Biol. 2014;180:8-11.
Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW. Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer. 2003;89(12):2197-201.
Shrivastava S, Katia AC, Barmon D, Deka P, Bhuyan C, Bhargav SJ. Gestational trophoblastic neoplasia: A 6 year retrospective study. South Asian J Cancer 2014; 3:33-7.
Abu-Rustum NR, Yashar CM, Bean S, Bradly K, Campos SM, Chon HS, et al. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cano Netw 2019; 17:1374-91.
Schink JC, Filiaci V, Huang HQ, Tidy J, Winter M, Carter J, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol 2020; 158:354-60.
Brown J, Naumann RW, Seckl MJ, Schink J. 15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol 2017; 144:200207.
Miller CR, Chappell NP, Sledge C, Leath CA, Phippen NT, Havrilesky LJ, et al. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? Gynecol Oncol 2017; 144:125-129.
Mangili G, Cioffi R, Danese S, Frigerio L, Ferrandina G, Cormio G, et al. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. Gynecol Oncol. 2018;151:449-52.
Maestá I, Horowitz NS, Goldstein DP, Bernstein MR, Ramírez LA, Moulder J, et al. Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2015;25:734-40.
Chalouhi GE, Golfier F, Soignon P, Massardier J, Guastalla JP, Trillet-Lenoir V, et al. Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol. 2009;200:643.
Uberti EM, Fajardo M, Cunha AG, Frota SS, Braga A, Ayub AC. Treatment of low risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37:258-65.
Berkowitz RS, Goldstein DP, Bernstein MR. Ten years’ experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol. 1986;23:111-8.